logo

For the Inventor, By the Inventor

London, United Kingdom

Convergence Pharmaceuticals Limited


USPTO Granted Patents = 24

% Expired Patents = 70.8


Forward Citations = 65

Loading Chart...
Loading Chart...

41 inventors (with patents filed for the assignee):

goldMedal Gerard M P Giblin (7 out of 7 patents)

silverMedal Steven J Stanway (7 out of 7 patents)

bronzeMedal David Witty (6 out of 10 patents)

4.  David MacPherson (5 out of 5 patents)

5.  Paul John Beswick (5 out of 29 patents)

6.  Robert James Gleave (5 out of 8 patents)

7.  Jag Paul Heer (5 out of 10 patents)

8.  Sadie Vile (5 out of 7 patents)

9.  Giuseppe Alvaro (4 out of 58 patents)

10.  David Norton (4 out of 16 patents)

11.  Andrew Peter Cridland (4 out of 20 patents)

12.  Markus Bergauer (4 out of 8 patents)

13.  Roberto Profeta (4 out of 6 patents)

14.  Simon Edward Ward (4 out of 15 patents)

15.  David T MacPherson (3 out of 4 patents)


24 patents:

1. 10493059 - Paroxysmal extreme pain disorder treatment (2019-12-03),
2. 10485801 - Pyrimidinyl-diazospiro compounds (2019-11-26),
3. 10421716 - Process for preparing alpha-carboxamide pyrrolidine derivatives (2019-09-24),
4. 10231950 - Erythromelalgia treatment (2019-03-19),
5. 10010551 - Pyrimidinyl-diazospiro compounds (2018-07-03),
6. 9750719 - Tetrazole compounds as calcium channel blockers (2017-09-05),
7. 9737536 - Pyrimidinyl-diazospiro compounds (2017-08-22),
8. 9376445 - Pyrimidinyl-diazospiro compounds (2016-06-28),
9. 9376436 - 2-(pyridin-2yl)-1, 7-diaza-spiro [4.4] nonane-6-one compound as voltage-gated sodium channels modulators (2016-06-28),
10. 9309254 - Pyrimidinyl-diazospiro compounds (2016-04-12),
11. 9303032 - 2-(pyridin-2YL)-1, 7-diaza-spiro [4.4] nonane-6-one compound as voltage-gated sodium channels modulator (2016-04-05),
12. 9115132 - Tetrazole compounds as calcium channel blockers (2015-08-25),
13. 9045485 - ASK 1 inhibiting pyrrolopyrimidine derivatives (2015-06-02),
14. 8933132 - Tricyclic substituted benzenesulfonamide piperazine derivatives as CAV2.2 calcium channel blockers (2015-01-13),
15. 8759542 - Process for preparing alpha-carboxamide derivatives (2014-06-24),
Company Overview
Convergence Pharmaceuticals Limited is a biopharmaceutical company based in London, specializing in the development of innovative therapies for pain management and neurological disorders. The organization focuses on advancing its proprietary drug candidates through rigorous research and clinical trials, aiming to address unmet medical needs in these critical areas. With a commitment to scientific excellence, Convergence Pharmaceuticals leverages cutting-edge technology and a deep understanding of disease mechanisms to create effective treatment solutions.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

Convergence Pharmaceuticals Limited USPTO Patent Assignee Logo
24 Patents

#154 in London

#738 in United Kingdom

#26,660 in the World

London, GB
London, United Kingdom

Convergence Pharmaceuticals Limited

Forward Citations = 65

41 inventors:

goldMedal Gerard M P Giblin (7 out of 7 patents)

silverMedal Steven J Stanway (7 out of 7 patents)

bronzeMedal David Witty (6 out of 10 patents)

4.  David MacPherson (5 out of 5 patents)

5.  Paul John Beswick (5 out of 29 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Convergence Pharmaceuticals Limited. Retrieved from https://idiyas.com/company/convergence-pharmaceuticals

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…